Global Antisense Oligonucleotide Therapeutics Market

Report ID : 1245 | Published : 2022-06-07 | Pages: | Format: PDF/EXCEL

The Global Antisense Oligonucleotide Therapeutics Market is estimated to reach over USD 64.46 billion by 2030, exhibiting a CAGR of 12.90% during the forecast period. 

Antisense oligonucleotide is crucial in present medicine because it inhibits the expression of disease-causing genes by acting on messenger RNA before the protein is produced. This is attributed to rising antisense drug acceptability, increased R&D funding, rising neurodegenerative disorders, and an ageing population. The antisense oligonucleotides market will benefit from a high number of regulatory approvals from the Food and Drug Administration (FDA), for the use of innovative antisense oligonucleotides medications. Furthermore, mergers and acquisitions to enhance their product offerings are expected to be a major driver for the worldwide antisense oligonucleotides market over the upcoming years.

However, the high cost of antisense oligonucleotide therapeutics and the availability of synthetic chemicals are factors projected to limit the overall growth of the antisense oligonucleotide therapeutics market over the coming years. In addition, developing a new set of unique regulatory requirements is a difficulty that is inhibiting the worldwide antisense oligonucleotide market's growth. Also, Investments by prominent players are factors expected to create lucrative growth opportunities in terms of revenue for players operating in the global Antisense Oligonucleotide Therapeutics market over the forecast period.

Market Segmentation:

The Antisense Oligonucleotide Therapeutics market is segmented based on Therapy, molecule target indication and target indication. Based on Therapy, the market is categorized into Monotherapy, Combination. Based on molecule target indication application, the market is segmented into DNA Molecule andrena Molecule. Based on target indication market is segmented into Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease and Others.

Based on Therapy, the monotherapy segment is accounted as a major contributor in the Antisense Oligonucleotide Therapeutics market

The Monotherapy category is expected to hold a major share in the global Antisense Oligonucleotide Therapeutics market in 2021. The market is expected to increase due to a rise in regulatory approvals of monotherapy medications. Furthermore, the increased prevalence of prostate cancer is expected to drive the market forward during the forecast period.

RNA Molecule segment witnessed growth at a rapid rate

The RNA Molecule segment is projected to grow at a rapid rate in the global Antisense Oligonucleotide Therapeutics market during the forecast period. Collaboration operations between pharmaceutical firms and Contract Research Organizations (CROs) focusing on drug delivery are projected to benefit the antisense & RNA molecule industry, particularly in nations such as the United States, Germany, the United Kingdom, China, and India. In addition, many other antisense technologies and oligonucleotide molecules are also being developed for non-neurodegenerative disorders.

In the region, the North America Antisense Oligonucleotide Therapeutics market holds a significant revenue share.

The North America Antisense Oligonucleotide Therapeutics market is expected to register the highest market share in terms of revenue soon. Several biotechnology companies have made significant expenditures on the development of RNAi therapeutics. Big pharmaceutical companies have gone into partnership or license arrangements with several smaller companies to profit from the predicted revenue increase in this industry over the projection period. Several medication candidates now undergoing clinical trials have shown promising results and are moving forward in the development process. If such studies continue to yield positive results, the North American market is likely to see a significant demand increase throughout the forecast period.

Europe is expected to be the dominant region in the global antisense oligonucleotides market over the forecast period. This is due to the region's rising approval of novel antisense oligonucleotide medications. In addition to enhancing their product offers in antisense oligonucleotides, key companies in Europe are focusing on strategic mergers and acquisitions.

Competitive Landscape

The key players in the Antisense Oligonucleotide Therapeutics market have shifted their focus towards bio-based components for product manufacturing and are initiating effective strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance product portfolio and strengthen their market footprint across the globe. Some of the major key players in the Antisense Oligonucleotide Therapeutics  market are Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Sarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc., Atlantic Pharmaceuticals, Inc., Enzo Pharmaceuticals, Inc., Bio-Path Holdings, Inc., Gene Signal International SA, GlaxoSmithKline plc, Gerona Corporation, Gradualist, ICO Therapeutics, Aptos Biosciences, Marina Biotech, mirage Therapeutics, Inc., Synodic, Inc., Oncogene Pharmaceuticals Inc., Pharm axis Ltd, Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc., and RI Pharmaceuticals, among others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Antisense Oligonucleotide Therapeutics Market Snapshot

Chapter 4. Global Antisense Oligonucleotide Therapeutics Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Clinical Trial/Pipeline Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. COVID 19 Impact Analysis

Chapter 5. Market Segmentation 1: By Therapy, Estimates & Trend Analysis

5.1. By Therapy, & Market Share, 2020 & 2028

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following By Therapy:

5.2.1. Monotherapy

5.2.2. Combination

Chapter 6. Market Segmentation 2: By Molecule Target Indication Estimates & Trend Analysis

6.1. By Molecule Target Indication & Market Share, 2020 & 2028

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following By Molecule Target Indication:

6.2.1. DNA Molecule

6.2.2. RNA Molecule

Chapter 7. Market Segmentation 3: By Target Indication Estimates & Trend Analysis

7.1. By Target Indication & Market Share, 2020& 2028

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following By Target Indication:

7.2.1. Duchenne Muscular Atrophy

7.2.2. Spinal Muscular Atrophy

7.2.3. Familial Chylomicronemia Syndrome

7.2.4. Amyotrophic Lateral Sclerosis

7.2.5. Familial Partial Lipodystrophy

7.2.6. Hereditary Transthyretin-Mediated (hATTR) Amyloidosis

7.2.7. Huntington’s Disease

7.2.8. Others

Chapter 8. Antisense Oligonucleotide Therapeutics Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2020-2028

8.1.2. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Target Indication, 2020-2028

8.1.3. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2020-2028

8.1.4. North America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2020-2028

8.2. Europe

8.2.1. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Therapy, 2020-2028

8.2.2. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Molecule Target Indication, 2020-2028

8.2.3. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Target Indication, 2020-2028

8.2.4. Europe Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) by Country, 2020-2028

8.3. Asia Pacific

8.3.1. Asia Pacific Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Therapy, 2020-2028

8.3.2. Asia Pacific Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Molecule Target Indication, 2020-2028

8.3.3. Asia Pacific Antisense Oligonucleotide Therapeutics Market revenue (US$ Million) By Target Indication, 2020-2028

8.3.4. Asia Pacific Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) by country, 2020-2028

8.4. Latin America

8.4.1. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Therapy, (US$ Million)

8.4.2. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Molecule Target Indication, (US$ Million)

8.4.3. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Target Indication, (US$ Million)

8.4.4. Latin America Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) by Country, (US$ Million) 2020-2028

8.5. Middle East & Africa

8.5.1. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Therapy, (US$ Million)

8.5.2. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Molecule Target Indication, (US$ Million)

8.5.3. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) By Target Indication, (US$ Million)

8.5.4. Middle East & Africa Antisense Oligonucleotide Therapeutics Market Revenue (US$ Million) by Country, (US$ Million) 2020-2028

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Antisense Therapeutics Limited

9.2.2. Atlantic Healthcare plc

9.2.3. Biogen Inc.

9.2.4. Bio-Path Holdings

9.2.5. Ionis Pharmaceuticals

9.2.6. ProQR Therapeutics

9.2.7. Roche

9.2.8. Sarepta Therapeutics

9.2.9. Sterna Biologicals

9.2.10. Nippon Shinyaku Co.

9.2.11. Wave Life Sciences

9.2.12. Other Prominent Player

Segmentation of Antisense Oligonucleotide Therapeutics Market-

By Therapy

  • Monotherapy
  • Combination

By Molecule Target Indication

  • DNA Molecule
  • RNA Molecule

By Target Indication

  • Duchenne Muscular Atrophy
  • Spinal Muscular Atrophy
  • Familial Chylomicronemia Syndrome
  • Amyotrophic Lateral Sclerosis
  • Familial Partial Lipodystrophy
  • Hereditary Transthyretin-Mediated (hatter) Amyloidosis
  • Huntington’s Disease
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients